6 reports of this reaction
20.0% of all CHELIDONIUM MAJUS reports
#1 most reported adverse reaction
LACTIC ACIDOSIS is the #1 most commonly reported adverse reaction for CHELIDONIUM MAJUS, manufactured by BM Private Limited. There are 6 FDA adverse event reports linking CHELIDONIUM MAJUS to LACTIC ACIDOSIS. This represents approximately 20.0% of all 30 adverse event reports for this drug.
Patients taking CHELIDONIUM MAJUS who experience lactic acidosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
LACTIC ACIDOSIS is a frequently reported adverse event for CHELIDONIUM MAJUS, accounting for a significant proportion of all reports.
In addition to lactic acidosis, the following adverse reactions have been reported for CHELIDONIUM MAJUS:
The following drugs have also been linked to lactic acidosis in FDA adverse event reports:
LACTIC ACIDOSIS has been reported as an adverse event in 6 FDA reports for CHELIDONIUM MAJUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
LACTIC ACIDOSIS accounts for approximately 20.0% of all adverse event reports for CHELIDONIUM MAJUS, making it one of the most commonly reported side effect.
If you experience lactic acidosis while taking CHELIDONIUM MAJUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.